These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. King-Robson J; Wilson H; Politis M; J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079 [TBL] [Abstract][Full Text] [Related]
8. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. Mouton-Liger F; Dumurgier J; Cognat E; Hourregue C; Zetterberg H; Vanderstichele H; Vanmechelen E; Bouaziz-Amar E; Blennow K; Hugon J; Paquet C Alzheimers Res Ther; 2020 Jul; 12(1):88. PubMed ID: 32690068 [TBL] [Abstract][Full Text] [Related]
9. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
11. Beyond the sleep-amyloid interactions in Alzheimer's disease pathogenesis. Ning S; Jorfi M J Neurophysiol; 2019 Jul; 122(1):1-4. PubMed ID: 30864847 [TBL] [Abstract][Full Text] [Related]
12. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D; Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532 [TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine-Metabolic Dysfunction and Sleep Disturbances in Neurodegenerative Disorders: Focus on Alzheimer's Disease and Melatonin. Spinedi E; Cardinali DP Neuroendocrinology; 2019; 108(4):354-364. PubMed ID: 30368508 [TBL] [Abstract][Full Text] [Related]
14. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease. Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499 [TBL] [Abstract][Full Text] [Related]
15. It's complicated: The relationship between sleep and Alzheimer's disease in humans. Lucey BP Neurobiol Dis; 2020 Oct; 144():105031. PubMed ID: 32738506 [TBL] [Abstract][Full Text] [Related]
16. Is Sleep Disruption a Cause or Consequence of Alzheimer's Disease? Reviewing Its Possible Role as a Biomarker. Lloret MA; Cervera-Ferri A; Nepomuceno M; Monllor P; Esteve D; Lloret A Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32050587 [TBL] [Abstract][Full Text] [Related]